Evaluation of the bleeding risk with various antithrombotic therapies after gastric endoscopic submucosal dissection

Abstract Background and study aims  Patients receiving antithrombotic drugs have a higher risk of postoperative bleeding and thromboembolic events related to endoscopic procedures. The aim of this study was to evaluate the relationship between various antithrombotic therapies and bleeding after gast...

Full description

Saved in:
Bibliographic Details
Published inEndoscopy International Open Vol. 5; no. 7; pp. E653 - E662
Main Authors Gotoda, Tatsuhiro, Hori, Keisuke, Iwamuro, Masaya, Kono, Yoshiyasu, Miura, Kou, Kanzaki, Hiromitsu, Kawano, Seiji, Kawahara, Yoshiro, Okada, Hiroyuki
Format Journal Article
LanguageEnglish
Published Stuttgart · New York Georg Thieme Verlag KG 01.07.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Background and study aims  Patients receiving antithrombotic drugs have a higher risk of postoperative bleeding and thromboembolic events related to endoscopic procedures. The aim of this study was to evaluate the relationship between various antithrombotic therapies and bleeding after gastric endoscopic submucosal dissection (ESD) (post-ESD bleeding). Patients and methods  Among 529 consecutive gastric ESD procedures (483 patients with 579 legions), 100 patients with 121 lesions who underwent 108 procedures were on antithrombotic therapy (group A) and 382 patients with 458 lesions who underwent 421 procedures were not on antithrombotic therapy (group B). The ratio of post-ESD bleeding between the two groups and the bleeding risk related to various antithrombotic therapies were investigated. Results  Postoperative bleeding was more frequent in group A (11.1 %) than in group B (3.3 %). No thromboembolic events were reported in either group. Further investigation of antithrombotic therapies in group A demonstrated that various combinations of antithrombotic agents and heparin replacement were associated with a higher ratio of post-ESD bleeding. Multivariate analyses revealed that dual antiplatelet therapy (odds ratio [OR] 10.9, 95 % confidence interval [CI] 2.1 – 49.5; P  = 0.005) and heparin replacement (OR 34.4, 95 %CI 9.4 – 133.2; P  < 0.001) were associated with the increased risk of post-ESD bleeding. In patients on antiplatelet therapy, post-ESD bleeding tended to occur in the early postoperative period compared with patients on anticoagulant therapy. Conclusions  It is necessary to be cautious regarding post-ESD bleeding in patients requiring antithrombotic therapy, especially patients receiving dual antiplatelet therapy and heparin replacement. A further prospective study with a large sample will be needed to confirm these findings.
ISSN:2364-3722
2196-9736
DOI:10.1055/s-0043-110050